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Background: MiR-155 has emerged as an “oncomiR”, which is the most significantly up-regulated miRNA in breast
cancer. However, the mechanisms of miR-155 functions as an oncomiR are mainly unknown. In this study, the aims
were to investigate the effects of miR-155 on cell proliferation, cell cycle, and cell apoptosis of ERalpha (+) breast
cancer cells and to verify whether TP53INP1 (tumor protein 53-induced nuclear protein 1) is a target of miR-155,
and tried to explore the mechanisms of miR-155 in this process.
Results: The expression of miR-155 is significantly higher in MCF-7 cells compared with MDA-MB-231 cells. Ectopic
expression of TP53INP1 inhibits growth of MCF-7 cells by inducing cell apoptosis and inhibiting cell cycle
progression. Overexpression of miR-155 increases cell proliferation and suppress cell apoptosis, whereas abrogating
expression of miR-155 suppress cell proliferation and promotes cell apoptosis of MCF-7 cells. In addition, miR-155
negatively regulates TP53INP1 mRNA expression and the protein expression of TP53INP1, cleaved-caspase-3, -8, -9,
and p21, and luciferase reporter reveals that TP53INP1 is targeted by miR-155.
Conclusions: TP53INP1 is the direct target of miR-155. MiR-155, which is overexpressed in MCF-7 cells, contributes
to proliferation of MCF-7 cells possibly through down-regulating target TP53INP1.
Keywords: MiR-155, TP53INP1 (tumor protein 53-induced nuclear protein 1), Proliferation, MCF-7 breast cancer cellsBackground
MicroRNAs (miRNAs) are a class of short (21–25 nt), on-
coding RNAs, which control their target genes expression
at the post-transcriptional level [1,2]. MiRNAs encoding
genes are mostly transcribed by RNA polymerase II by
Drosha into short hairpin RNAs, which are then exported
from the nucleus, and processed by Dicer to form mature
21–25 nucleotide miRNAs, which are finally transferred to
Argonaute proteins in RISC [3,4]. MiRNAs act on gene
expression by binding to the 3'-untranslated region
(3'UTR) of the target mRNAs, resulting in mRNA cleavage
and/or translational inhibition, thereby down-regulating
target proteins expression [5]. In fact, almost 30% of the
protein-coding genes are under the regulation of miRNAs,
and miRNAs have been implicated in the regulation of
various biological functions, including cell proliferation,* Correspondence: cqdenghy@yahoo.com.cn
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reproduction in any medium, provided the orapoptosis, and cell differentiation [6]. Therefore, miRNA
dysfunction may contribute to a variety of human diseases,
including cancer [7]. MiRNAs exert their function as on-
cogenes or tumor suppressor genes depending on their
target genes.
MiR-155, located in chromosome 21q21, is encoded with
a region known as B cell integration cluster (BIC) gene,
which consists of three exons within a 13 kb region [8].
The human BIC gene is activated by promoter insertion and
lacks a long open reading frame [8]. MiR-155 represents a
typical multifunctional miRNA, which is overexpressed in a
variety of human solid tumors such as breast cancer [9-12],
lung cancer [13,14], thyroid tumor [15], pancreatic cancer
[16-19]. These recent clinical pathologic data indicate that
miR-155 plays a crucial role in tumor development and
tumor diagnosis and prognosis. The available experimental
evidences indicate that miR-155 promotes some tumors
growth, invasion, and metastasis through inhibits down-
stream targets such as SHIP1 [20], C/EBPbeta [21], andLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Primers used for real-time quantitative PCR
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that miR-155 functions as an oncomiR in human
cancer.
MiR-155 has been found to be up-regulated in breast
cancer and is closely related to the status of estrogen recep-
tor (ER) and progesterone receptor (PR) [9,22], its tumori-
genesis role has not yet been defined. In this study, we
identified that TP53INP1 is one of the targets of miR-155
in ERalpha (+) MCF-7 cells. Furthermore, we found that
overexpression of miR-155 promoted cell proliferation and
inhibited apoptosis through the repression of TP53INP1 in
MCF-7 cells. In addition, in this study, we indicated that
miR-155 significantly repressed cell cycle and apoptosis-
related gene caspase-3, -8, -9, and p21 expression. These re-
sults revealed that miR-155 is an oncomiR in breast cancer,




Four synthetic, chemically modified short RNA oligonu-
cleotides: miR-155 mimics (miR-155 m, 5'-UUAAUGCU
AAUCGUGAUAGGGGUCCCUAUCACGAUUAGCAUU
AAUU-3'), miR-155 mimics negative control (miR-155 m
NC, Sense: 5'-UUCUCCGAACGUGUCACGUTT-3';
Anti-sense: 5'-ACGUGACACGUUCGGAGAATT-3'),
miR-155 inhibitors (miR-155i, 5'-ACCCCUAUCACG
AUUAGCAUUAA-3') and miR-155 inhibitors negative
control (miR-155i NC, 5'-CAGUACUUUUGUGUAGU
ACAA-3') were purchased from Shanghai GenePharma Co.
Ltd. The TP53INP1 overexpression plasmid and control
plasmid were purchased from Wuhan Sanying Company
and subcloned into pcDNA3. TP53INP1 3'UTR reporter
plasmids pYr-MirTarget, pYr-MirTarget-TP53INP1-3U
(pMIR-TP53INP1-3U) and pYr-MirTarget-TP53INP1-3U-M
(pMIR-TP53INP1-3U-M) were purchased from Changsha
Yingrun Biotechnology Co.Ltd.
Cell culture and transfection
Human MCF-7, MDA-MB-231 cells were provided by
Staff Room of Pathophysiology, Chongqing Medical Uni-
versity and were maintained DMEM (Gibco) or RPMI1640
(Gibco) media supplemented with 10% NBCS (Gibco, New
Zealand), penicillin (100 U/ml), and streptomycin (100 μg/
ml). Cells were maintained in sterile conditions at 37°C in
a humidified atmosphere of 5% CO2. Cells were seeded
into 6-well plates grown overnight and reached 30-50%
confluence before transfection. Transfection of MCF-7
cells with miR-155 m (or miR-155i) or counterpart nega-
tive control using lipfectamine™ 2,000 transfection reagent
(Invitrogen, USA) according to the manufacturer’s instruc-
tion. The experiments were classified into three groups,
which were miR-155 m (or miR-155i) group, miR-155 m
NC (or miR-155i NC) group and control (Con) group.Transfection of MCF-7 cells withTP53INP1 overexpression
plasmid or control plasmid using lipfectamine™ 2,000 trans-
fection reagent.
RNA isolation and real-time quantitative PCR
For quantification of miR-155 and TP53INP1 mRNA by
real-time PCR, total miRNA, and total RNA were isolated
from cultured cells with MiRNA rapid extraction kit and
RNApure rapid extraction kit (Bioteke Corporation, Beijing,
China) according to the manufacturer’s instructions. Re-
verse transcription was performed using Moloney murine
leukemia virus reverse transcriptase (Bioteke Corporation,
Beijing, China). MiR-155 was reverse transcripted by
looped primers with the sequence of 5'-GTCGTATCCA
GTGCAGGGTCCGAGGTATTCGCACTGGATACGACA
CCCCT-3', while reverse transcription of TP53INP1 mRNA
was performed with Oligo dT primers (Bioteke Corporation,
Beijing, China). Real-time PCR was performed using the
LightCycle RNA amplification kit SYBR Green (Bioteke
Corporation, Beijing, China) according to the manufacturer’s
protocols. U6 snRNA and β-actin served as an endogenous
control for normalization. Real-time PCR reactions were
performed on a CFX96 real-time PCR detection system from
Bio-Rad Co.LTD (America), with cycle threshold values eval-
uated using the manufacturer’s software. The expression of
miR-155, TP53INP1 mRNA, relative to U6 snRNA,
β-actin, were calculated using the 2-ΔΔCT method. The
real-time PCR primers are shown in Table 1.Cell proliferation assay
The cell viability was evaluated by CCK8 assay according
to the manufacturer’s instructions. In brief, cells were
seeded into 96-well plates with 4,000 cells/well at 12 h
post-transfection. Afterward 10 μl of CCK8 was added to
each well, and the culture medium was incubated at 37°C
for additional 3 h. Absorbance at 450 nm wavelength was
detected using Eliasa. The absorbance at 450 nm shows
mitochondrial activity, and it indirectly reflects living cell
number, which indicates cell viability. Each experiment
was performed at least in triplicate.
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Cell cycle analysis was performed using the standard
propidium iodide (PI) method. In brief, cells were
trypsinized, washed with cold PBS, fixed in 70% ethanol for
24 h, and stained with PI for 30 min. Finally, the cells were
analyzed by flow cytometry (FCM). Each experiment was
performed at least in triplicate.
Cell apoptosis assay
The apoptosis was analyzed by FCM. Apoptotic cells were
differentiated from viable or necrotic ones by combined
application of annexin V-FITC and PI. The samples were
washed twice and adjusted to a concentration of 1×106
cells/ml with cold PBS. 10 μl of annexin V-FITC and 10 μl
PI were added into 100 μl of cell suspension, incubated for
15 min at room temperature in the dark. Finally, 400 μl of
binding buffer was added to each sample without washing
and analyzed using FCM. Each experiment was performed
at least in triplicate.
Western blot analysis
Protein samples were separated by 12% SDS-PAGE and
transferred to PVDF membranes (Millipore). After blocked
2 h with 5% milk, the PVDF membranes were then incu-
bated with TP53INP1 (rabbit anti-human polyclonal anti-
body; 1:100, Santa Cruz), pro-caspase-3 (rabbit anti-human
monoclonal antibody; 1:1,000, epitomics), cleaved-caspase-
3 (rabbit anti-human monoclonal antibody; 1:1,000,
Beyotime), caspase-8 (rabbit anti-human monoclonal anti-
body; pro-caspase-8: 1:1,000, cleaved-caspase-8: 1:500,
Beyotime), caspase-9 (mouse anti- human monoclonal
antibody; 1:1,000, Beyotime), and p21 (mouse anti- human
monoclonal antibody; 1:200, Beyotime) overnight at 4°C.
Following extensive washing for a total of 45 min, mem-
branes were incubated with secondary antibody goat anti-
rabbit IgG (1:5,000, Beijing 4A Biotech Co.Ltd) and goat
anti-mouse IgG (1:5,000, Beijing 4A Biotech Co.Ltd) for
2 h. After washing three times for a total of 45 min with
TBST at room temperature, chemiluminescent detectionFigure 1 The expression levels of ERalpha and miR-155 in MCF-7 and
western blot of protein extracts from ERalpha (+) MCF-7 and ERalpha (−) M
MCF-7 and MDA-MB-231 cells. The expression of miR-155 in MCF-7 cells wa
repeated at least three times.was performed with the BeyoECL Plus kit (Beyotime), and
membranes were exposed to Kodak XBT-1 films.
Luciferase report assay
The pYr-MirTarget-Report plasmids for miR-155 target
TP53INP1 3'UTR were constructed as pMIR-TP53INP1-
3U containing the wild-type 3'UTR of TP53INP1 and as
pMIR-TP53INP1-3U-M containing the mutant 3'UTR of
TP53INP1. The pMIR-TP53INP1-3U vector and pMIR-
TP53INP1-3U-M vector contain Firefly luciferase and
Renilla luciferase. 293 cells were seeded into 96-well plates,
and each was co-transfected with pMIR-TP53INP1-3U vec-
tor or pMIR-TP53INP1-3U-M vector and 50 nM miR-
155 m or miR-155 m NC according to the manufacturer’s
protocol. After 48 h transfection, luciferase activity was mea-
sured with the Dual Luciferase Assay system (Promega).
Renilla luciferase activity was normalized to Firefly lucifer-
ase activity (Renilla LUC/ Firefly LUC). Each experiment
was performed at least three times.
Statistical analysis
Each experiment was performed in triplicate, and repeated
at least three times. The data were shown as the mean ±
SD, and differences were compared between 3-group using
one-way ANOVA and 2-group using t tests. The P ≤ 0.05
was considered to be statistically significant.
Results
Differential expression of miR-155 between MCF-7 and
MDA-MB-231 cells
ERalpha expression was monitored by western blot analysis,
using as control extracts from ERalpha (−) MDA-MB-231
cells (Figure 1A). In our study, we found that miR-155 ex-
pression was significantly higher in MCF-7 cells with
ERalpha (+) compared with MDA-MB-231 cells with
ERalpha (−) using real-time PCR analysis. As shown in
Figure 1B, the expression of miR-155 in MCF-7 cells was
3.05-fold that of MDA-MB-231 cells and the difference had
statistical significance.MDA-MB-231 cells. (A) Expression level of ERalpha was detected by
DA-MB-231 cells. (B) Differential expression of miR-155 between
s 3.05-fold that of MDA-MB-231cells. **P < 0.01. All experiments were
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cells by inducing cell apoptosis and inhibiting cell
cycle progression
MCF-7 cells were transfected with TP53INP1 over-
expression plasmid or control plasmid, and CCK8 assay
showed there was a significant reduction in the growth of
TP53INP1-expressing cells compared to those transfected
with the control plasmid (Figure 2A).
To elucidate the mechanism of growth inhibition of
TP53INP1-expressing MCF-7 cells, we analyzed their cell
cycle and cell apoptosis rate. Overexpression of TP53INP1
resulted in a significant increase in the percentage of cellsFigure 2 TP53INP1 inhibits MCF-7 cell proliferation and promotes cel
TP53INP1 overexpression plasmid or control plasmid. *P < 0.05 and **P < 0.01 v
overexpression plasmid or control plasmid. **P < 0.01 versus control. (C) FCM a
plasmid or control plasmid. **P < 0.01 versus control. Data are presented as mein the G1 phase indicating a G1 cell cycle arrest (Figure 2B).
FCM assay showed that overexpression of TP53INP1 in-
creased cell apoptosis rate compared with the control plas-
mid (Figure 2C). These data revealed that TP53INP1
inhibited the growth of MCF-7 cells by inducing cell apop-
tosis and inhibiting cell cycle progression.
TP53INP1 is a target of miR-155 in breast cancer cells
To study the mechanisms and carcinogenic function of
miR-155 on the development of breast cancer, TargetScan,
Pictar-Vert, and microRNA.Org were using for this pur-
pose. In combinational predicted with the three softwares,l apoptosis. (A) CCK8 analysis of cell viability after transfection with
ersus control. (B) FCM analysis of cell cycle after transfection with TP53INP1
nalysis of cell apoptosis rate after transfection with TP53INP1 overexpression
an ± SD. All experiments were repeated at least three times.
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155. The TP53INP1 3'UTR carries a binding site for miR-
155 (Figure 3A), suggesting that TP53INP1 might be a
direct target of miR-155. Therefore, we determined that
whether overexpression of miR-155 led to down-regulation
of TP53INP1 expression in human breast cancer cells.
Real-time quantitative PCR analyses showed that the
TP53INP1 mRNA level was down-regulated by ~45%
when miR-155 was overexpression ~69-fold (Figure 4A,
4C). In contrast, the TP53INP1 mRNA level was up-
regulated by ~1.5-fold when miR-155 was down-regulated
by ~87% (Figures 4B, 4D). Moreover, western blot assay
indicated that transfection with miR-155 m led to nearly
78% down-regulation of TP53INP1 in MCF-7 cells com-
pared with Con or miR-155 m NC group, whereas treat-
ment with miR-155i induced 359% increase of TP53INP1
compared with Con or miR-155i NC group (Figure 3C).
To understand these negative regulate relationship be-
tween miR-155 and TP53INP1, we constructed plasmids
containing wild-type or mutant 3'UTR of TP53INP1 fused
to the luciferase gene (Figure 3B). The wild-type or mu-
tant plasmid was co-transfected into 293 cells with miR-
155 m or miR-155m NC. As shown in Figure 3D, miR-155
significantly decreased the luciferase activity of wild-type
3'UTR of TP53INP1, whereas the luciferase activity with
mutant 3'UTR of TP53INP1 was not repressed by miR-
155, suggesting that miR-155 could directly bind to the
3'UTR of TP53INP1. Taken together, these findings
showed that TP53INP1 is a direct target of miR-155 inFigure 3 TP53INP1 is a target of miR-155 in MCF-7 cells. (A) Putative b
predicted by TargetScan. (B) Sketch of the construction of pMIR-TP53INP1-
underlined. (C) TP53INP1 protein level was measured by western blot at 72
*P < 0.05 versus Con, miR-155 m NC or miR-155i NC. (D) miR-155 m down
but did not affect luciferase activity controlled by mutant TP53INP1 3'UTR.
pYr-MirTarget+155 m, pMIR-TP53INP1-3U-M+155 m. All experiments were rbreast cancer cells and mRNA degradation is involved in
miR-155-suppressing TP53INP1.MiR-155 promoted cell proliferation and inhibited cell
apoptosis of MCF-7 cells
To investigate the biologic effects of miR-155, cell prolifer-
ation, cell cycle, and cell apoptosis were measured after dif-
ferential transfection. As shown in Figure 5A, treatment
with miR-155 m significantly promoted the growth of
MCF-7 cells compared with Con or miR-155 m NC. MiR-
155i, but not the miR-155i NC significantly inhibited the
growth of MCF-7 cells compared with Con (Figure 5B).
Next, we detected the effect of miR-155 on cell cycle,
found that miR-155 significantly increased S and G2 phase
population, but had more profound effect on G1
phase population compared with Con or miR-155 m NC
(Figure 6A). G1 phase population of MCF-7 cells
transfected with miR-155i was increased, and S and G2
phase population was reduced compared with Con or miR-
155i NC (Figure 6B). Moreover, FCM assay was performed
to detect the effect of miR-155 on cell apoptosis of MCF-7
cells. As shown in Figures 6C, 6D, transfected with miR-
155 m could significantly reduce cell apoptosis rate of
MCF-7 cells compared with Con or miR-155 m NC, and
transfected with miR-155i increased cell apoptosis rate
compared with Con or miR-155i NC. These data sug-
gested that miR-155 might function as an oncogene in
MCF-7 cells.inding sites of miR-155 in the TP53INP1 3'UTR (white sequences)
3U or pMIR-TP53INP1-3U-M vectors. The mutant binding site is
h post-transfection. Data are presented as mean ± SD. **P < 0.01 and
-regulated luciferase activity controlled by wild-type TP53INP1 3'UTR,
*P < 0.05 versus pMIR-TP53INP1-3U+155 m NC and **P < 0.01 versus
epeated at least three times.
Figure 4 Analysis of the expression levels of miR-155 and TP53INP1 mRNA after differential treatment. (A) Expression level of miR-155
after transfection with miR-155 m. Data are presented as mean ± SD. **P < 0.01 versus Con, miR-155 m NC. (B) Expression level of miR-155 after
transfection with miR-155i. **P < 0.01 versus Con, miR-155i NC. (C) Expression level of TP53INP1 mRNA after transfection with miR-155 m. *P <
0.05 versus Con, miR-155 m NC. (D) Expression level of TP53INP1 mRNA after transfection with miR-155i. *P < 0.05 versus Con, miR-155i NC. All
experiments were repeated at least three times.
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cleaved-caspase-3, -8, -9, and p21 in MCF-7 cells
To verify the role of miR-155 in protein expression of
caspase-3, -8, -9, and p21, MCF-7 cells were transfected
with miR-155 m or miR-155i. Treatment with miR-155 m
induced 87%, 65%, 68%, and 33% reduced in cleaved-
caspase-3, -8, -9, and p21 compared with Con or miR-
155 m NC, whereas transfection with miR-155i led to
nearly 97%, 90%, 159%, and 60% up-regulation of cleaved-
caspase-3, -8, -9, and p21 compared with Con or miR-155i
NC (Figure 7). These data suggested that cell cycle and
apoptosis-related protein caspase-3, -8, -9, and p21 were
possible the potential downstream genes of TP53INP1.Figure 5 Cell proliferation of MCF-7 cells after differential treatment.
differential times. *P < 0.05 and **P < 0.01 versus Con, miR-155 m NC. (B) C
differential times. *P < 0.05 and **P < 0.01 versus Con, miR-155i NC. The OD
at least three times.Discussion
The mechanisms of miR-155 functions as an oncomiR are
largely unknown. Our study here was to investigate the
effects of miR-155 on cell proliferation, cell cycle and cell
apoptosis of ERalpha (+) breast cancer cells and to verify
whether TP53INP1 is a target of miR-155, and tried to
explore the mechanisms of miR-155 in this process.
In our study, we found that miR-155 expression was sig-
nificantly higher in ERalpha (+) MCF-7 cells than ERalpha
(−) MDA-MB-231 cells. Moreover, we observed that up-
regulation of miR-155 significantly stimulated cell growth
and inhibited cell apoptosis in MCF-7 cells, which was
consistent with results that blocking miR-155 using miR-(A) CCK8 analysis of cell viability after transfection with miR-155 m at
CK8 analysis of cell viability after transfection with miR-155i at
value reflects cell viability indirectly. All experiments were repeated
Figure 6 Cell cycle and cell apoptosis rate of MCF-7 cells after differential treatment. (A) FCM analysis of cell cycle after transfection with
miR-155 m. (B) FCM analysis of cell cycle after transfection with miR-155i. (C) FCM analysis of cell apoptosis rate after transfection with miR-
155 m. (D) FCM analysis of cell apoptosis rate after transfection with miR-155i. Data are presented as mean ± SD. **P<0.01 and *P < 0.05 versus
Con, miR-155 m NC or miR-155i NC. All experiments were repeated at least three times.
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apoptosis. But, how miR-155 might functions inside cells
accounting for the effects of miR-155 on biologic behavior
of MCF-7 cells. To study the mechanisms and carcino-
genic function of miR-155 on the development of breast
cancer, TargetScan, Pictar-Vert, and microRNA.Org were
using for this purpose. In combinational predicted with the
three softwares, we found that TP53INP1 was a potential
target of miR-155. Therefore, we focused our attention on
TP53INP1 signal pathways.The main pathway in human breast cancer involve
p53, which acts as a multifunctional transcription factor,
exerts its tumor suppressor function mainly through
transcriptional induction of target genes involved in
several processes, including cell cycle checkpoints and
apoptosis [23]. TP53INP1, one of the p53 target genes,
is a p53-inducible cell stress response gene [24,25]
located on the chromosome 8q22 [26]. Its expression is
dependent on the activation of wide-type p53 [27]. Ori-
ginally, TP53INP1 expression is strongly induced in
Figure 7 MiR-155 negatively regulated protein expression of cleaved-caspase-3, -8, -9, and p21 in MCF-7 cells. (A) Protein expression
levels of p21 and cleaved-caspase-3 after transfection with miR-155 m. (B) Protein expression levels of p21 and cleaved-caspase-3 after
transfection with miR-155i. (C) Protein expression levels of cleaved-caspase-8, -9 after transfection with miR-155 m. (D) Protein expression levels of
cleaved-caspase-8, -9 after transfection with miR-155i. The protein expression levels of cleaved-caspase-3, -8, -9, and p21 were detected by
western blot and normalized to that of β-actin. Data are presented as mean ± SD. **P < 0.01 and *P < 0.05 versus Con, miR-155 m NC or miR-
155i NC. All experiments were repeated at least three times.
Zhang et al. Journal of Biomedical Science 2013, 20:79 Page 8 of 10
http://www.jbiomedsci.com/content/20/1/79mice with acute pancreatitis in vivo [24], and also in
several cell lines under exposure to various stress agents
in vitro [25,27,28]. Overexpression of TP53INP1, which
is a tumor suppressor gene, induces cell cycle arrest as
well as enhances the p53-mediated apoptosis [27]. In
our study, we have also showed that ectopic expression
of TP53INP1 inhibited growth of MCF-7 cells by indu-
cing cell apoptosis and inhibiting cell cycle progression.
Moreover, recent findings have shown a significant re-
duction of the expression of TP53INP1 during the de-
velopment of breast cancer [29], stomach cancer [30],
and pancreas cancer [18]. TP53INP1 expression was in-
vestigated immunohistochemically in 81 cases of breast
carcinoma, compared with normal breast tissue, de-
creased TP53INP1 expression was found in 45 cases
(55.6%) [29]. The expression level of TP53INP1 was in-
versely linked to high histological grade, tumor size, posi-
tive lymph node metastasis, and aberrant p53 expression
[29]. Besides, it had been reported that TP53INP1-positive
rate decreased with the progression of gastric cancer; and
TP53INP1 protein negativity was significantly associated
with aggressive pathological phenotypes of gastric cancer
[30,31]. These observations suggest that TP53INP1 playsa crucial role in suppression of tumor progression
including breast cancer through its anti-proliferative
and pro-apoptotic activities. Our data showed that
overexpression of miR-155 not only led to the down-
regulation of TP53INP1 but also inversed the effect of
TP53INP1 by promoting cell proliferation and suppress-
ing cell apoptosis. Restoration of TP53INP1 by knockdown
of miR-155 using miR-155 inhibitors was accompanied by
decreased cell proliferation and enhanced cell apoptosis.
The conclusion that miR-155 negatively regulated the pro-
tein expression of TP53INP1 was further supported by data
showing that miR-155 significantly decreased the relative
luciferase activity of TP53INP1 3'UTR. MiR-155 can dir-
ectly repress TP53INP1 expression through binding to the
binding sites in the 3'UTR of TP53INP1, thereby negatively
regulating TP53INP1 function. Thus, we have reasons to
believe that TP53INP1 is possible the target gene of miR-
155 in MCF-7 cells.
Apoptosis is a process of programmed cell death that
plays a crucial role in both normal growth and maintaining
cellular homeostasis, and regulated by numerous signaling
pathways [32]. Dysregulated apoptosis is caused by the
changes in the expression and activation of key apoptotic
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plays a key role in coordinating the stereotypical events that
occur during apoptosis. Caspases are classified into two
groups according to their structure and function: the up-
stream initiator, such as caspase-8, -9, and −10, and the
downstream executioner, such as caspase-3, -6, and-7 [34].
Cell cycle arrest is closely linked to apoptosis. P21 is
cyclin-dependent kinase inhibitor located in p53 gene
downstream, and plays a key role in cell cycle G0/G1 ar-
rest. Our data showed that down-regulation of TP53INP1
by miR-155 correlated with down-regulation of cleaved-
caspase-3, -8, -9, and p21. It indicated that TP53INP1 reg-
ulates cell cycle and induces cell apoptosis may be by
down-regulating p21 and activating caspase way.
Conclusions
In summary, our researches suggest that miR-155 func-
tions as an oncomiR by targeting TP53INP1 and contrib-
utes to the control of cell survival and growth in breast
cancer cells. Tumor suppressor gene TP53INP1 is nega-
tively regulated by miR-155 and mediates miR-155 func-
tions in inducing cell proliferation and inhibiting cell
apoptosis. Therefore, TP53INP1 is identified to be the dir-
ect target of miR-155. The findings may be providing a
new therapeutic strategy for breast cancer.
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